You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDobutamine
Accession NumberDB00841  (APRD00122)
TypeSmall Molecule
GroupsApproved
DescriptionA beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.
Structure
Thumb
Synonyms
(+-)-4-(2-((3-(P-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
4-{2-[3-(4-hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol
DL-Dobutamine
Dobutamin
Dobutamina
Dobutamine
Dobutaminum
rac-Dobutamine
Racemic-dobutamine
External Identifiers
  • 46236
  • 81929
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dobutamine 12.5mg/mlSolution12.5 mgIntravenousIvax Pharmaceuticals Incorporated1996-11-252015-10-26Canada
Dobutamine HydrochlorideInjection, solution400 mg/100mLIntravenousPhysicians Total Care, Inc.2007-06-13Not applicableUs
Dobutamine Hydrochloride In DextroseInjection400 mg/100mLIntravenousBaxter Healthcare Corporation1993-09-23Not applicableUs
Dobutamine Hydrochloride In DextroseInjection, solution100 mg/100mLIntravenousHospira, Inc.1993-10-19Not applicableUs
Dobutamine Hydrochloride In DextroseInjection100 mg/100mLIntravenousBaxter Healthcare Corporation1993-09-27Not applicableUs
Dobutamine Hydrochloride In DextroseInjection, solution200 mg/100mLIntravenousHospira, Inc.1993-10-19Not applicableUs
Dobutamine Hydrochloride In DextroseInjection200 mg/100mLIntravenousBaxter Healthcare Corporation1993-09-27Not applicableUs
Dobutamine Hydrochloride In DextroseInjection, solution400 mg/100mLIntravenousHospira, Inc.1993-10-19Not applicableUs
Dobutamine Hydrochloride Injection USPSolution12.5 mgIntravenousHospira Healthcare Corporation1996-10-24Not applicableCanada
Dobutamine Hydrochloride Injection-12.5mg/mlLiquid12.5 mgIntravenousSanofi Canada, Inc.1997-05-211998-10-24Canada
Dobutamine Hydrochloride Injection-12.5mg/mlLiquid12.5 mgIntravenousNovopharm Limited1997-02-01Not applicableCanada
Dobutamine Injection SdzSolution12.5 mgIntravenousSandoz Canada Incorporated2013-12-04Not applicableCanada
Dobutamine Injection USPSolution12.5 mgIntravenousSterimax IncNot applicableNot applicableCanada
Dobutamine Injection USPLiquid12.5 mgIntravenousSandoz Canada Incorporated2000-10-02Not applicableCanada
DobutrexSolution12.5 mgIntravenousPharmaceutical Partners Of Canada Inc1988-12-312008-02-13Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DobutamineInjection, solution12.5 mg/mLIntravenousHospira, Inc.1995-02-16Not applicableUs
DobutamineInjection, solution12.5 mg/mLIntravenousPhysicians Total Care, Inc.2006-12-11Not applicableUs
DobutamineInjection, solution12.5 mg/mLIntravenousGENERAL INJECTABLES AND VACCINES, INC.2014-11-10Not applicableUs
Dobutamine HydrochlorideInjection, solution, concentrate12.5 mg/mLIntravenousHospira, Inc.1993-11-29Not applicableUs
Dobutamine HydrochlorideInjection, powder, lyophilized, for solution12.5 mg/mLIntravenousGeneral Injectables & Vaccines, Inc2010-03-012016-11-04Us
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DobujectBayer
DobusafeClaris
DobutaminSandoz
DobutanDemo
DobutelNovell
DobutilMeizler
DopminMylan Seiyaku
InotrexLilly
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dobutamine hydrochloride
Thumb
  • InChI Key: BQKADKWNRWCIJL-UHFFFAOYNA-N
  • Monoisotopic Mass: 337.144471346
  • Average Mass: 337.841
DBSALT000711
Categories
UNII3S12J47372
CAS number34368-04-2
WeightAverage: 301.3801
Monoisotopic: 301.167793607
Chemical FormulaC18H23NO3
InChI KeyJRWZLRBJNMZMFE-UHFFFAOYSA-N
InChI
InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3
IUPAC Name
4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol
SMILES
CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1
Pharmacology
IndicationFor inotropic support in the short- term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures
Structured Indications
PharmacodynamicsDobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with little effect on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine. Dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.
Mechanism of actionDobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
agonist
HumanP08588 details
Beta-2 adrenergic receptorProteinunknown
agonist
HumanP07550 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationIn human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine.
Half life2 minutes
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Dobutamine Action PathwayDrug actionSMP00662
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Dobutamine.Experimental
AcebutololAcebutolol may decrease the bronchodilatory activities of Dobutamine.Approved
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Dobutamine.Approved, Investigational
AlprenololAlprenolol may decrease the bronchodilatory activities of Dobutamine.Approved, Withdrawn
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Dobutamine.Illicit, Withdrawn
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dobutamine.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Dobutamine.Approved, Illicit
AtenololAtenolol may decrease the bronchodilatory activities of Dobutamine.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Dobutamine.Approved
AtosibanThe risk or severity of adverse effects can be increased when Dobutamine is combined with Atosiban.Approved
BendroflumethiazideDobutamine may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Dobutamine.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Benzphetamine.Approved, Illicit
Benzylpenicilloyl PolylysineDobutamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Betahistine.Approved
BetaxololBetaxolol may decrease the bronchodilatory activities of Dobutamine.Approved
BisoprololBisoprolol may decrease the bronchodilatory activities of Dobutamine.Approved
BopindololBopindolol may decrease the bronchodilatory activities of Dobutamine.Approved
BromocriptineBromocriptine may increase the hypertensive activities of Dobutamine.Approved, Investigational
BucindololThe risk or severity of adverse effects can be increased when Dobutamine is combined with Bucindolol.Investigational
BumetanideDobutamine may increase the hypokalemic activities of Bumetanide.Approved
BupranololBupranolol may decrease the bronchodilatory activities of Dobutamine.Approved
CabergolineCabergoline may increase the hypertensive activities of Dobutamine.Approved
CalciumThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Dobutamine.Withdrawn
CarteololCarteolol may decrease the bronchodilatory activities of Dobutamine.Approved
CarvedilolCarvedilol may decrease the vasoconstricting activities of Dobutamine.Approved, Investigational
CeliprololCeliprolol may decrease the bronchodilatory activities of Dobutamine.Approved, Investigational
ChlorothiazideDobutamine may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Chlorphentermine.Illicit, Withdrawn
ChlorthalidoneDobutamine may increase the hypokalemic activities of Chlorthalidone.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Dobutamine is combined with Clenbuterol.Approved, Vet Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dobutamine.Approved, Vet Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dobutamine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Dobutamine.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Dobutamine.Approved
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Dobutamine.Approved
DopamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Dopamine.Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Dobutamine.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Dobutamine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Dobutamine.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Doxofylline.Approved
DronabinolDronabinol may increase the tachycardic activities of Dobutamine.Approved, Illicit
DuloxetineDuloxetine may increase the tachycardic activities of Dobutamine.Approved
EntacaponeThe metabolism of Dobutamine can be decreased when combined with Entacapone.Approved, Investigational
EphedrineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Ephedrine.Approved
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Dobutamine.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Dobutamine.Approved
ErgonovineErgonovine may increase the hypertensive activities of Dobutamine.Approved
ErgotamineErgotamine may increase the hypertensive activities of Dobutamine.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Dobutamine.Investigational
EsmololEsmolol may decrease the bronchodilatory activities of Dobutamine.Approved
Etacrynic acidDobutamine may increase the hypokalemic activities of Etacrynic acid.Approved
EtilefrineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Etilefrine.Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Dobutamine is combined with Fenoterol.Approved
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Dobutamine.Approved, Vet Approved
FurosemideDobutamine may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Dobutamine.Approved
HydrochlorothiazideDobutamine may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideDobutamine may increase the hypokalemic activities of Hydroflumethiazide.Approved
Hydroxyamphetamine hydrobromideThe risk or severity of adverse effects can be increased when Dobutamine is combined with Hydroxyamphetamine hydrobromide.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Dobutamine.Approved
IndapamideDobutamine may increase the hypokalemic activities of Indapamide.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Dobutamine.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Dobutamine.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Dobutamine.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Dobutamine.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dobutamine.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Isoprenaline.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Isoxsuprine.Approved, Withdrawn
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Dobutamine.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Dobutamine.Approved
LinezolidLinezolid may increase the hypertensive activities of Dobutamine.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Dobutamine.Withdrawn
MephentermineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Mephentermine.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Dobutamine.Approved, Investigational
MethamphetamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Methamphetamine.Approved, Illicit
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Dobutamine.Approved
MethyclothiazideDobutamine may increase the hypokalemic activities of Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Dobutamine.Investigational
MetolazoneDobutamine may increase the hypokalemic activities of Metolazone.Approved
MetoprololMetoprolol may decrease the bronchodilatory activities of Dobutamine.Approved, Investigational
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Dobutamine.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Dobutamine.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Dobutamine.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dobutamine.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Dobutamine.Approved
NabiloneNabilone may increase the tachycardic activities of Dobutamine.Approved, Investigational
NadololNadolol may decrease the bronchodilatory activities of Dobutamine.Approved
NebivololNebivolol may decrease the bronchodilatory activities of Dobutamine.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Dobutamine.Withdrawn
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Dobutamine.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Dobutamine.Approved
NylidrinThe risk or severity of adverse effects can be increased when Dobutamine is combined with Nylidrin.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Dobutamine.Withdrawn
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Dobutamine.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Dobutamine.Approved
OxprenololOxprenolol may decrease the bronchodilatory activities of Dobutamine.Approved
OxymetazolineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Oxymetazoline.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Dobutamine.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Dobutamine.Approved, Investigational
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dobutamine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Dobutamine.Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Dobutamine.Approved, Illicit
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Dobutamine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Dobutamine.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Dobutamine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Dobutamine.Approved, Vet Approved, Withdrawn
PindololPindolol may decrease the bronchodilatory activities of Dobutamine.Approved
PiretanideDobutamine may increase the hypokalemic activities of Piretanide.Experimental
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Dobutamine.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Dobutamine.Withdrawn
PolythiazideDobutamine may increase the hypokalemic activities of Polythiazide.Approved
PrazosinPrazosin may decrease the vasoconstricting activities of Dobutamine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Dobutamine is combined with Procaterol.Approved
PropranololPropranolol may decrease the bronchodilatory activities of Dobutamine.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dobutamine.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Pseudoephedrine.Approved
QuinethazoneDobutamine may increase the hypokalemic activities of Quinethazone.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Racepinephrine.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dobutamine.Approved
RitodrineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Ritodrine.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Dobutamine.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Dobutamine.Approved, Investigational, Vet Approved
SilodosinSilodosin may decrease the vasoconstricting activities of Dobutamine.Approved
SotalolSotalol may decrease the bronchodilatory activities of Dobutamine.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Dobutamine.Approved
SynephrineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Synephrine.Experimental
TamsulosinTamsulosin may decrease the vasoconstricting activities of Dobutamine.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Dobutamine.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Dobutamine.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Terbutaline.Approved
Testosterone PropionateThe metabolism of Dobutamine can be decreased when combined with Testosterone Propionate.Approved, Vet Approved
TetryzolineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Tetryzoline.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Dobutamine.Approved
TimololTimolol may decrease the bronchodilatory activities of Dobutamine.Approved
TolcaponeThe metabolism of Dobutamine can be decreased when combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Dobutamine.Approved
TorasemideDobutamine may increase the hypokalemic activities of Torasemide.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dobutamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dobutamine.Approved
TrichlormethiazideDobutamine may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Dobutamine.Experimental
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dobutamine.Approved
TyramineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Tyramine.Investigational, Nutraceutical
VenlafaxineVenlafaxine may increase the tachycardic activities of Dobutamine.Approved
Food InteractionsNot Available
References
Synthesis Reference

R. R. Tuttle, J. Mills, DE 2317710 (1973).
J. Mills, R. R. Tuttle, U.S. Patent 3,987,200 (1976).

US5442120
General ReferencesNot Available
External Links
ATC CodesC01CA07
AHFS Codes
  • 12:12.08.08
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9937
Blood Brain Barrier-0.7448
Caco-2 permeable+0.5305
P-glycoprotein substrateSubstrate0.7571
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.6336
CYP450 2C9 substrateNon-substrate0.7235
CYP450 2D6 substrateSubstrate0.6265
CYP450 3A4 substrateNon-substrate0.5296
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8231
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8827
Ames testNon AMES toxic0.7215
CarcinogenicityNon-carcinogens0.9306
BiodegradationNot ready biodegradable0.9256
Rat acute toxicity2.2261 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.828
hERG inhibition (predictor II)Inhibitor0.8367
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Astrazeneca lp
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Marsam pharmaceuticals llc
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Baxter healthcare corp
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous12.5 mg/mL
Injection, powder, lyophilized, for solutionIntravenous12.5 mg/mL
Injection, solutionIntravenous400 mg/100mL
Injection, solution, concentrateIntravenous12.5 mg/mL
InjectionIntravenous100 mg/100mL
InjectionIntravenous200 mg/100mL
InjectionIntravenous400 mg/100mL
Injection, solutionIntravenous100 mg/100mL
Injection, solutionIntravenous200 mg/100mL
SolutionIntravenous12.5 mg
LiquidIntravenous12.5 mg
Prices
Unit descriptionCostUnit
Dobutamine 12.5 mg/ml vial0.18USD ml
Dobutamine 250 mg-d5w 500 ml0.09USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point184-186J. Mills, R. R. Tuttle, U.S. Patent 3,987,200 (1976).
logP3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0137 mg/mLALOGPS
logP2.97ALOGPS
logP2.62ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)10.14ChemAxon
pKa (Strongest Basic)9.27ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area72.72 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity88.39 m3·mol-1ChemAxon
Polarizability34.44 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as catecholamines and derivatives. These are compounds containing 4-(2-Aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] or a derivative thereof formed by substitution.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenols and derivatives
Direct ParentCatecholamines and derivatives
Alternative Parents
Substituents
  • Catecholamine
  • Phenylpropylamine
  • Phenethylamine
  • Aralkylamine
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Junker V, Becker A, Huhne R, Zembatov M, Ravati A, Culmsee C, Krieglstein J: Stimulation of beta-adrenoceptors activates astrocytes and provides neuroprotection. Eur J Pharmacol. 2002 Jun 20;446(1-3):25-36. [PubMed:12098582 ]
  2. La Rosee K, Huntgeburth M, Rosenkranz S, Bohm M, Schnabel P: The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines. Pharmacogenetics. 2004 Nov;14(11):711-6. [PubMed:15564877 ]
  3. Bruck H, Leineweber K, Temme T, Weber M, Heusch G, Philipp T, Brodde OE: The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol. 2005 Dec 6;46(11):2111-5. Epub 2005 Nov 4. [PubMed:16325050 ]
  4. Raddatz A, Kubulus D, Winning J, Bauer I, Pradarutti S, Wolf B, Kreuer S, Rensing H: Dobutamine improves liver function after hemorrhagic shock through induction of heme oxygenase-1. Am J Respir Crit Care Med. 2006 Jul 15;174(2):198-207. Epub 2006 Apr 20. [PubMed:16627864 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Tibayan FA, Chesnutt AN, Folkesson HG, Eandi J, Matthay MA: Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):438-44. [PubMed:9279221 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
O-methyltransferase activity
Specific Function:
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.
Gene Name:
COMT
Uniprot ID:
P21964
Molecular Weight:
30036.77 Da
References
  1. Raxworthy MJ, Youde IR, Gulliver PA: Catechol-O-methyltransferase: substrate-specificity and stereoselectivity for beta-adrenoceptor agents. Xenobiotica. 1986 Jan;16(1):47-52. [PubMed:2868577 ]
  2. Yan M, Webster LT Jr, Blumer JL: Kinetic interactions of dopamine and dobutamine with human catechol-O-methyltransferase and monoamine oxidase in vitro. J Pharmacol Exp Ther. 2002 Apr;301(1):315-21. [PubMed:11907189 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23